Search

We investigated the effect of a synthetic lipid A analogue with low endotoxicity, DT-5461, on the neovascularization induced by B16-BL6 melanoma in syngeneic mice. A systemic single administration of DT-5461 caused a marked decrease in the number of vessels oriented toward the tumor mass and in the tumor size during the early phase of vasculogenesis (on day 4 after tumor inoculation), with little or no inhibition in the following phases. Multiple i.v. administrations of DT-5461 at intervals of 4 days (an effective schedule for inhibiting tumor metastasis) significantly reduced the number of capillary vessels and tumor growth over a period of 14 days after the tumor implantation. Multiple systemic administrations of DT-5461 on days 1, 5 and 9 after tumor inoculation caused a high production of endogenous tumor necrosis factor-alpha (TNF-alpha) in tumor sites although this treatment modality induced a low production in serum of tumor-bearing mice. Tumor homogenate from mice treated with DT-5461 suppressed the proliferation of endothelium in vitro, whereas sera from animals given DT-5461 had little effect. Furthermore, the antiproliferative effect of the tumor homogenate from mice treated with DT-5461, was completely abrogated by anti-mTNF-alpha monoclonal antibody (mAb). The anti-angiogenic effect of DT-5461 was also completely abrogated by rabbit anti-mouse tumor necrosis factor-alpha (anti-mTNF-alpha) antiserum, whereas the inhibition of tumor growth by DT-5461 was only slightly diminished. Tumor homogenate from mice treated with DT-5461 suppressed the proliferation of endothelium in vitro, whereas sera from animals given DT-5461 had little effect. Furthermore, the antiproliferative effect of the tumor homogenate from mice treated with DT-5461 was completely neutralized by anti-mTNF-alpha mAb. Multiple i.v. administrations of DT-5461 after s.c. implantation of B16-BL6 cells significantly inhibited the growth of primary tumors measured at the time of tumor excision on day 21, and the lung metastasis of melanoma cells as compared with the untreated control in the spontaneous metastasis model. These results suggested that the suppressive effect upon tumor-associated angiogenesis by DT-5461 contributes in part to the inhibition of tumor metastasis.

We have investigated the antimetastatic effect of a new synthetic lipid A analogue, of low endo-toxicity, DT-5461, against two highly metastatic tumor cell lines, L5178Y-ML25 T-lymphoma and B16-BL6 melanoma cells in mice. Four intermittent i.v. administrations of DT-5461 at intervals of 4 days resulted in a significant inhibition of liver metastasis caused by i.v. injection of L5178Y-ML25 cells and lung metastasis of B16-BL6 cells in the experimental metastasis models. Intraperitoneal and intranasal administrations as well as i.v. administration of DT-5461 were also effective in preventing lung metastasis of the melanoma cells. Multiple administrations of DT-5461 before the surgical excision of primary tumors significantly reduced the number of lung colonies of melanoma cells and primary tumor size. Similarly, this treatment modality after the surgical excision of primary tumors showed a greater reduction of lung tumor colonies as compared with lipopolysaccharide, a synthetic lipid A (No. 506) and its analogue as well as untreated control in the spontaneous lung metastasis model. Furthermore, the group that received DT-5461 after the inoculation of lymphoma or melanoma cells showed significantly enhanced survival rate compared with the untreated control. These results suggested that DT-5461 may he therapeutically useful for the inhibition of tumor metastasis.